UY37142A - Nuevos indazoles 2-sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen,así como su uso para la preparación de medicamentos - Google Patents

Nuevos indazoles 2-sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen,así como su uso para la preparación de medicamentos

Info

Publication number
UY37142A
UY37142A UY0001037142A UY37142A UY37142A UY 37142 A UY37142 A UY 37142A UY 0001037142 A UY0001037142 A UY 0001037142A UY 37142 A UY37142 A UY 37142A UY 37142 A UY37142 A UY 37142A
Authority
UY
Uruguay
Prior art keywords
preparation
well
new
procedures
endometriosis
Prior art date
Application number
UY0001037142A
Other languages
English (en)
Inventor
Holger Siebeneicher Dr
Nicole Schmidt Dra
Judith Günther Dra
Holger Steuber Dr
Ulf Bömer Dr
Martin Lange Dr
Reinhard Nubbemeyer Dr
Pascal Savy
Charles Ray Nicholas
Ulrich Bothe Dr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY37142A publication Critical patent/UY37142A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se refiere a nuevos indazoles 2-sustituidos, a procedimientos para su preparación, el uso de los nuevos indazoles sustituidos para el tratamiento y/o la profilaxis de enfermedades, así como su uso para la preparación de medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular para el tratamiento y/o la profilaxis de endometriosis así dolores asociados a la endometriosis y otros síntomas de endometriosis como dismenorrea, dispareunia, disuria y disquecia, de linfomas, artritis reumatoidea, espondiloartritis (en particular espondiloartritis psoriásica y enfermedad de Bechterew), lupus eritematoso sistémico, esclerosis múltiple, degeneración macular, EPOC, gota, afecciones por hígado graso, resistencia a la insulina, enfermedades tumorales y psoriasis.
UY0001037142A 2016-03-03 2017-03-03 Nuevos indazoles 2-sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen,así como su uso para la preparación de medicamentos UY37142A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16158542 2016-03-03

Publications (1)

Publication Number Publication Date
UY37142A true UY37142A (es) 2017-10-31

Family

ID=55451138

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037142A UY37142A (es) 2016-03-03 2017-03-03 Nuevos indazoles 2-sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen,así como su uso para la preparación de medicamentos

Country Status (9)

Country Link
US (1) US10435396B2 (es)
EP (1) EP3423446B1 (es)
JP (1) JP6947743B2 (es)
CN (1) CN109153665B (es)
AR (1) AR107795A1 (es)
CA (1) CA3016364A1 (es)
TW (1) TW201734004A (es)
UY (1) UY37142A (es)
WO (1) WO2017148902A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
CU24593B1 (es) 2016-04-29 2022-05-11 Bayer Pharma AG Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)- piridin-2-carboxamida
SI3448846T1 (sl) 2016-04-29 2021-09-30 Bayer Pharma Aktiengesellschaft Sinteza indazolov
SG11201810769QA (en) 2016-06-01 2018-12-28 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
US11897863B2 (en) * 2018-08-17 2024-02-13 Zhejiang Hisun Pharmaceutical Co., Ltd. Indazole amine derivative, preparation method therefor and medical use thereof
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
CN112654604B (zh) * 2018-09-06 2023-05-16 浙江海正药业股份有限公司 7-取代吲唑类衍生物及其制备方法和其在医药上的用途
WO2020135513A1 (zh) * 2018-12-25 2020-07-02 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111793064B (zh) * 2019-04-02 2023-06-23 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
JP2022539374A (ja) * 2019-06-27 2022-09-08 バイオジェン・エムエイ・インコーポレイテッド ２ｈ－インダゾール誘導体及び疾患の処置におけるそれらの使用
WO2020264499A1 (en) 2019-06-28 2020-12-30 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3152167C (en) * 2019-09-24 2023-12-19 Guozhong YE Irak inhibitor and preparation method therefor and use thereof
WO2021259163A1 (zh) 2020-06-23 2021-12-30 上海美悦生物科技发展有限公司 一种稠和吡唑类化合物的制备方法
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
CN114404415A (zh) * 2022-02-25 2022-04-29 上海美悦生物科技发展有限公司 吲唑类化合物用于治疗银屑病的用途
CN116003324A (zh) * 2022-12-26 2023-04-25 杭州澳赛诺生物科技有限公司 一种6-氯-2-甲基-2η-吲唑-5-胺的合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
JP2003277383A (ja) 2002-03-14 2003-10-02 Bayer Ag 光学活性ピリジン誘導体およびそれを含む医薬
US20070179143A1 (en) 2003-06-25 2007-08-02 Je Il Pharmaceutical Co., Ltd. Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
JP2008523046A (ja) 2004-12-08 2008-07-03 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー メチレン誘導体
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
WO2007091107A1 (en) 2006-02-10 2007-08-16 Summit Corporation Plc Treatment of duchenne muscular dystrophy
US20100173941A1 (en) 2006-06-09 2010-07-08 Astrazeneca Ab Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia
CN101616910A (zh) 2006-09-07 2009-12-30 比奥根艾迪克Ma公司 作为白细胞介素-1受体相关激酶调节剂的吲唑衍生物
GB0716414D0 (en) 2007-08-22 2007-10-03 Syngenta Participations Ag Novel insecticides
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
US20140113898A1 (en) 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
ES2592713T3 (es) 2010-12-20 2016-12-01 Merck Serono S.A. Derivados de indazolil-triazol como inhibidores de IRAK
US8748432B2 (en) 2011-02-10 2014-06-10 Syngenta Participations Ag Microbiocidal pyrazole derivatives
CA2827311A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
JP6234444B2 (ja) 2012-05-21 2017-11-22 バイエル ファーマ アクチエンゲゼルシャフト チエノピリミジン類
HUE029559T2 (en) 2012-07-10 2017-03-28 Ares Trading Sa Pyrimidine-pyrazolyl derivatives
US9126984B2 (en) 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
JP2017505337A (ja) * 2014-01-10 2017-02-16 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ４阻害剤としてのインダゾール化合物
KR102392684B1 (ko) 2014-01-13 2022-04-29 오리진 디스커버리 테크놀로지스 리미티드 Irak4 억제제로서의 바이시클릭 헤테로시클릴 유도체
KR20170016500A (ko) * 2014-06-20 2017-02-13 오리진 디스커버리 테크놀로지스 리미티드 Irak4 저해제로서의 치환된 인다졸 화합물
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
PL3224269T3 (pl) * 2014-11-27 2020-08-24 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
EP3288558B1 (en) 2015-04-30 2022-05-11 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
EA201890307A1 (ru) * 2015-07-15 2018-10-31 Ориджин Дискавери Текнолоджиз Лимитед Индазольные и азаиндазольные соединения как ингибиторы irak-4
CU24593B1 (es) 2016-04-29 2022-05-11 Bayer Pharma AG Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)- piridin-2-carboxamida
SI3448846T1 (sl) 2016-04-29 2021-09-30 Bayer Pharma Aktiengesellschaft Sinteza indazolov
SG11201810769QA (en) 2016-06-01 2018-12-28 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
MY199070A (en) 2016-06-01 2023-10-12 Bayer Pharma AG Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals

Also Published As

Publication number Publication date
US10435396B2 (en) 2019-10-08
AR107795A1 (es) 2018-06-06
CN109153665A (zh) 2019-01-04
EP3423446A1 (de) 2019-01-09
CA3016364A1 (en) 2017-09-08
WO2017148902A1 (de) 2017-09-08
CN109153665B (zh) 2021-10-15
EP3423446B1 (de) 2020-09-16
JP6947743B2 (ja) 2021-10-13
JP2019507168A (ja) 2019-03-14
TW201734004A (zh) 2017-10-01
US20190071432A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
UY37142A (es) Nuevos indazoles 2-sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen,así como su uso para la preparación de medicamentos
DOP2017000127A (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.
UY37048A (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
CL2016001579A1 (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos.
BR112019018863A8 (pt) Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
AR099289A1 (es) Proteínas de fusión de interleucina-2 y usos de las mismas
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
GT201700184A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2018003438A1 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos.
DOP2015000100A (es) Inhibidores de la tirosina-quinasa de bruton
BR112017008157A2 (pt) polipeptídeos de fgf-21 modificados e usos dos mesmos
ECSP15042779A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
UY36166A (es) Formas de sales de n—(cianometil)—4—(2—(4—morfolinofenilamino)pirimidin—4—il)benzamida, sus composiciones y su uso terapeutico
UY37267A (es) Nuevos benzimidazoles sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CL2016000026A1 (es) Nuevos derivados de azabencimidazol
DOP2016000290A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
CO2017001918A2 (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
GT201700126A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos
DOP2016000289A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
MD20150017A2 (ro) Utilizarea preparatului Polibiolin la pacienţii cu ciroză hepatică

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230601